BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a
rapidly growing commercial-stage specialty pharmaceutical company
dedicated to patients living with chronic conditions, today
reported strong financial results for the third quarter ended
September 30, 2019, as well as the following operational and
performance highlights.
Key Business Highlights:
- Total Company net revenue increased by 114% versus the prior
year period to a new all-time high of $30.3 million. This
growth was driven by BELBUCA® (buprenorphine buccal film),
CIII sales of $26.5 million, an increase of 115% versus the prior
year period, and the addition of Symproic® (naldemedine) tablets
0.2mg to the commercial portfolio.
- Total BELBUCA prescriptions of more than 89,600 for the quarter
were the highest ever for any three-month period. In
addition, BELBUCA achieved record year over year prescription
volume growth of more than 45,000 during the quarter.
- Total Symproic prescriptions reached an all-time high of
15,686, representing more than 39% growth versus the prior year
period.
- Achieved record number of unique prescribers during the quarter
for both BELBUCA and Symproic.
- Significantly improved insurance coverage for BELBUCA by adding
an additional 14 million covered lives within commercial and health
exchange plans with preferred status as of January 1, 2020.
This brings the total commercial coverage for BELBUCA to more than
90% of covered lives, with approximately 60% being in preferred
status.
- Achieved substantial increase in insurance coverage for
Symproic by adding more than 14 million commercial covered lives
having preferred or preferred exclusive coverage by January 1,
2020, bringing the total commercial coverage for Symproic to more
than 40% in preferred or preferred exclusive status.
- Strong presence at the PAINWeek® 2019 National Conference on
Pain for Frontline Practitioners, including the presentation of
five scientific posters about BELBUCA and Symproic.
“The third quarter was, once again, highlighted by very strong
performance and achievements across the entire organization,”
stated Herm Cukier, CEO of BDSI. “We continue to see significant
growth momentum for BELBUCA and positive indicators of growth
emerging for Symproic. The success achieved in the third
quarter marks the sixth straight quarter of sustained rapid growth
and fuels our confidence to raise total net sales expectations for
full year 2019 and provide expectations for 2020. Given the
increased utilization by physicians, significantly expanded access
across payers, and tailwinds from federal health policy
initiatives, I believe BELBUCA and Symproic are positioned for
sustained growth.”
The Company raised expectations for full year 2019 total net
sales to $105 - $110 million from the previous level of $101 - $105
million, and reiterated the expectation to be operationally cash
flow positive during the fourth quarter. In addition, BDSI
provided full year 2020 BELBUCA net sales expectations of $150 –
$160 million and total Company net sales expectations of $165 –
$175 million.
Third Quarter 2019 Financial Results
Total Net Revenue. Total net revenue for
the third quarter ended September 30, 2019 was $30.3 million, an
increase of 114% compared to $14.2 million in the third quarter of
2018, and an increase of 2% compared to $29.7 million in the second
quarter of 2019.
BELBUCA Net Sales in the third quarter were
$26.5 million, an increase of 115% compared to $12.4 million in the
third quarter of 2018, and an increase of 10% compared to $24.1
million in the second quarter of 2019.
Symproic Net Sales in the third quarter were
$2.2 million, $1.0 million below the second quarter net sales which
had benefited from an agreed fee as part of a distribution
agreement with Shionogi. The third quarter was the first full
quarter of commercialization following acquisition of the product
and reflects a standard gross to net revenue deductions
approach.
Bunavail® Net Sales in the third quarter were
$0.9 million, a reduction of $0.5 million compared to the third
quarter of 2018 and an increase of $0.1 million compared to the
second quarter of 2019.
Product Royalty Revenue in the third quarter
was $0.7 million, an increase of $0.3 million compared to the third
quarter of 2018 and a reduction of $0.9 million compared to the
second quarter of 2019.
Total Operating Expenses. Total operating
expenses in the quarter ended September 30, 2019 were $23.4
million, compared to $22.0 million in the second quarter of 2019
and $14.2 million in the third quarter of 2018. The growth
compared to the second quarter of 2019 reflects ongoing investments
in marketing, sales and medical affairs.
GAAP Net Income. GAAP net income for the
quarter was $0.4 million compared to GAAP net loss of $11.1 million
for the second quarter of 2019 and GAAP net loss of $6.4 million in
the third quarter of 2018.
EBITDA in the third quarter of 2019 was $3.5
million or 11.6% of net sales, compared to $4.8 million in the
second quarter of 2019 and ($2.3) million in the third quarter of
2018.
Non-GAAP Net Income. Non-GAAP net income for
the quarter was $3.5 million and reflects GAAP net income excluding
stock-based compensation and non-cash amortization of intangible
assets.
Cash Position. As of September 30, 2019, cash
and cash equivalents were approximately $55.9 million, compared to
cash and cash equivalents of $43.8 million as of December 31,
2018.
Conference Call & Webcast Details
BioDelivery Sciences will host a conference call and
webcast today, November 12, 2019, at 4:30 p.m. ET to
present third quarter 2019 results and to provide a business
update. Dial-in details are as follows:
Date: |
Tuesday, November 12, 2019 |
Time: |
4:30 PM EST |
Domestic: |
877-407-0789 |
International: |
201-689-8562 |
Passcode: |
13696283 |
Webcast: |
http://public.viavid.com/index.php?id=136899 |
|
|
ABOUT BIODELIVERY SCIENCES INTERNATIONAL,
INC.
BioDelivery Sciences International,
Inc. (NASDAQ: BDSI) is a commercial-stage specialty
pharmaceutical Company dedicated to patients living with chronic
conditions. BDSI has built a portfolio of products that includes
utilizing its novel and proprietary BioErodible MucoAdhesive
(BEMA®) technology to develop and commercialize, either on its own
or in partnership with third parties, new applications of proven
therapies aimed at addressing important unmet medical needs. BDSI's
marketed products and those in development address serious and
debilitating conditions such as chronic pain, breakthrough cancer
pain, opioid dependence, and opioid-induced constipation.
CAUTIONARY NOTE ON FORWARD-LOOKING
STATEMENTS
This press release and any statements of
employees, representatives, and partners of BioDelivery
Sciences International, Inc. (“BDSI”) related thereto contain,
or may contain, among other things, certain “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve
significant risks and uncertainties. Such statements may include,
without limitation, statements with respect to the BDSI’s plans,
objectives, projections, expectations and intentions and other
statements identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “potential” or similar
expressions. These statements are based upon the current beliefs
and expectations of the BDSI’s management and are subject to
significant risks and uncertainties, including those detailed in
the BDSI’s filings with the Securities and Exchange
Commission. Actual results (including, without limitation, the
continued growth in long-term combined BELBUCA and Symproic net
sales and BELBUCA net sales and total company net revenue in 2019
and 2020 and the implementation and success of our Symproic
strategic plan) may differ materially from those set forth or
implied in the forward-looking statements. These forward-looking
statements involve certain risks and uncertainties that are subject
to change based on various factors (many of which are beyond the
BDSI’s control) including those set forth in our 2019 annual report
on Form 10-K filed with the US Securities and Exchange
Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
Non-GAAP Financial Measures
This press release includes information about certain financial
measures that are not prepared in accordance with generally
accepted accounting principles in the United States, or GAAP,
including non-GAAP net income and EBITDA. These non-GAAP measures
are not based on any standardized methodology prescribed by GAAP
and are not necessarily comparable to similar measures presented by
other companies.
Non-GAAP net income adjusts for one-time and non-cash charges by
excluding from GAAP results: stock-based compensation expense,
amortization of intangible assets, amortization of certain warrant
discount costs and the financial impact of our debt refinancing
which closed in May 2019, as it is non-recurring.
EBITDA excludes net interest, including both interest expenses
and interest income, provision for (benefit from) income taxes and
depreciation and amortization.
The Company's management and board of directors utilize these
non-GAAP financial measures to evaluate the Company's performance.
The Company provides these non-GAAP measures of the Company's
performance to investors because management believes that these
non-GAAP financial measures, when viewed with the Company's results
under GAAP and the accompanying reconciliations, are useful in
identifying underlying trends in ongoing operations. However,
non-GAAP net income and EBITDA are not measures of financial
performance under GAAP and, accordingly, should not be considered
as alternatives to GAAP measures as indicators of operating
performance. Further, non-GAAP net income and EBITDA should
not be considered measures of our liquidity.
A reconciliation of certain GAAP to non-GAAP financial measures
has been provided in the tables included in this press release.
© 2019 BioDelivery Sciences International,
Inc. All rights reserved.
Contact:
Tirth PatelDirector of Investor Relations(919)
582-0294tpatel@bdsi.com
BIODELIVERY SCIENCES INTERNATIONAL,
INC. AND SUBSIDIARIESCONDENSED
CONSOLIDATED BALANCE SHEETS(U.S. DOLLARS, IN
THOUSANDS, EXCEPT SHARE AND PER SHARE
AMOUNTS)(Unaudited)
|
September 30, 2019 |
|
December 31, 2018 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
55,863 |
|
|
$ |
43,822 |
|
Accounts receivable, net |
33,422 |
|
|
13,627 |
|
Inventory, net |
10,766 |
|
|
5,406 |
|
Prepaid expenses and other current assets |
4,874 |
|
|
3,188 |
|
Total current assets |
104,925 |
|
|
66,043 |
|
Property and equipment, net |
3,713 |
|
|
3,072 |
|
Goodwill |
2,715 |
|
|
2,715 |
|
License and distribution rights,
net |
62,044 |
|
|
36,000 |
|
Other intangible assets, net |
211 |
|
|
703 |
|
Total assets |
$ |
173,608 |
|
|
$ |
108,533 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable and accrued liabilities |
$ |
46,545 |
|
|
$ |
21,539 |
|
Total current liabilities |
46,545 |
|
|
21,539 |
|
Notes payable, net |
58,515 |
|
|
51,652 |
|
Other long-term liabilities |
654 |
|
|
5,600 |
|
Total liabilities |
105,714 |
|
|
78,791 |
|
Commitments and
contingencies |
|
|
|
Stockholders’ equity: |
|
|
|
Preferred Stock, 5,000,000 shares authorized; Series A Non-Voting
Convertible Preferred Stock. $.001 par value, 2,093,155 shares
outstanding at both September 30, 2019 and December 31,
2018, respectively; Series B Non-Voting Convertible Preferred
Stock, $.001 par value, 1,698 and 3,100 shares outstanding at
September 30, 2019 and December 31, 2018,
respectively. |
2 |
|
|
2 |
|
Common Stock, $.001 par value; 175,000,000 shares authorized at
September 30, 2019 and 125,000,000 shares authorized at
December 31, 2018, respectively; 89,796,774 and 70,793,725
shares issued;89,781,283 and 70,778,234 shares outstanding at
September 30, 2019 and December 31, 2018,
respectively. |
90 |
|
|
71 |
|
Additional paid-in capital |
433,746 |
|
|
381,004 |
|
Treasury stock, at cost, 15,491 shares |
(47 |
) |
|
(47 |
) |
Accumulated deficit |
(365,897 |
) |
|
(351,288 |
) |
Total stockholders’ equity |
67,894 |
|
|
29,742 |
|
Total liabilities and
stockholders’ equity |
$ |
173,608 |
|
|
$ |
108,533 |
|
|
|
|
|
|
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC.
AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS(U.S. DOLLARS, IN THOUSANDS, EXCEPT
SHARE AND PER SHARE
AMOUNTS)(Unaudited)
|
Three months ended September 30, |
|
Nine months ended September 30, |
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Revenues: |
|
|
|
|
|
|
|
Product sales |
$ |
29,623 |
|
|
$ |
13,763 |
|
|
$ |
77,438 |
|
|
$ |
34,367 |
|
Product royalty revenues |
683 |
|
|
370 |
|
|
2,154 |
|
|
2,197 |
|
Contract revenues |
— |
|
|
23 |
|
|
160 |
|
|
1,047 |
|
Total Revenues: |
30,306 |
|
|
14,156 |
|
|
79,752 |
|
|
37,611 |
|
Cost of sales |
5,350 |
|
|
3,779 |
|
|
14,325 |
|
|
11,760 |
|
Expenses: |
|
|
|
|
|
|
|
Research and development |
— |
|
|
699 |
|
|
— |
|
|
4,038 |
|
Selling, general and administrative |
23,360 |
|
|
13,489 |
|
|
62,304 |
|
|
41,013 |
|
Total Expenses: |
23,360 |
|
|
14,188 |
|
|
62,304 |
|
|
45,051 |
|
Income (loss) from
operations |
1,596 |
|
|
(3,811 |
) |
|
3,123 |
|
|
(19,200 |
) |
Interest expense |
(1,234 |
) |
|
(2,567 |
) |
|
(17,732 |
) |
|
(7,598 |
) |
Other (expense) income, net |
(3 |
) |
|
(2 |
) |
|
5 |
|
|
(8 |
) |
Income (loss) before income
taxes |
$ |
359 |
|
|
$ |
(6,380 |
) |
|
$ |
(14,604 |
) |
|
$ |
(26,806 |
) |
Income tax expense |
(5 |
) |
|
— |
|
|
(5 |
) |
|
(53 |
) |
Net income (loss) |
$ |
354 |
|
|
$ |
(6,380 |
) |
|
$ |
(14,609 |
) |
|
$ |
(26,859 |
) |
Beneficial conversion feature of
convertible preferred stock |
— |
|
|
(12,500 |
) |
|
— |
|
|
(12,500 |
) |
Net income (loss) attributable to
common stockholders |
$ |
354 |
|
|
$ |
(18,880 |
) |
|
$ |
(14,609 |
) |
|
$ |
(39,359 |
) |
Basic |
|
|
|
|
|
|
|
Weighted average common stock
shares outstanding |
89,649,922 |
|
|
64,900,007 |
|
|
81,612,112 |
|
|
60,599,456 |
|
Basic earnings (loss) per
share |
$ |
— |
|
|
$ |
(0.29 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.65 |
) |
Diluted |
|
|
|
|
|
|
|
Weighted average common stock
shares outstanding |
105,138,894 |
|
|
64,900,007 |
|
|
81,612,112 |
|
|
60,599,456 |
|
Diluted earnings (loss) per
share |
$ |
— |
|
|
$ |
(0.29 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.65 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC.
AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS(U.S. DOLLARS, IN
THOUSANDS)(Unaudited)
|
Nine months ended September 30, |
|
2019 |
|
2018 |
Operating activities: |
|
|
|
Net loss |
$ |
(14,609 |
) |
|
$ |
(26,859 |
) |
Adjustments to reconcile net loss to net cash flows from operating
activities |
|
|
|
Depreciation and amortization |
253 |
|
|
685 |
|
Impairment loss on equipment |
— |
|
|
78 |
|
Accretion of debt discount and loan costs |
11,441 |
|
|
2,953 |
|
Amortization of intangible assets |
5,084 |
|
|
3,868 |
|
Provision for inventory obsolescence |
57 |
|
|
396 |
|
Stock-based compensation expense |
3,978 |
|
|
4,896 |
|
Changes in assets and liabilities, net of effect of
acquisition: |
|
|
|
Accounts receivable |
(19,795 |
) |
|
(3,581 |
) |
Inventories |
(5,416 |
) |
|
261 |
|
Prepaid expenses and other assets |
(1,686 |
) |
|
(545 |
) |
Accounts payable and accrued liabilities |
14,844 |
|
|
(427 |
) |
Net cash flows used in operating activities |
(5,849 |
) |
|
(18,275 |
) |
Investing activities: |
|
|
|
Product acquisitions |
(20,674 |
) |
|
(1,951 |
) |
Acquisitions of equipment |
(79 |
) |
|
(155 |
) |
Net cash flows used in investing activities |
(20,753 |
) |
|
(2,106 |
) |
Financing activities: |
|
|
|
Proceeds from issuance of common stock |
48,000 |
|
|
— |
|
Proceeds from issuance of Series B preferred stock |
— |
|
|
50,000 |
|
Equity issuance costs |
(410 |
) |
|
(1,410 |
) |
Proceeds from notes payable |
60,000 |
|
|
— |
|
Proceeds from exercise of stock options |
1,193 |
|
|
528 |
|
Payment on note payable |
(67,346 |
) |
|
— |
|
Loss on refinancing of former debt |
(2,794 |
) |
|
— |
|
Payment of deferred financing fees |
— |
|
|
(450 |
) |
Net cash flows provided by financing activities |
38,643 |
|
|
48,668 |
|
Net change in cash and cash
equivalents |
12,041 |
|
|
28,287 |
|
Cash and cash equivalents at
beginning of period |
43,822 |
|
|
21,195 |
|
Cash and cash
equivalents at end of period |
$ |
55,863 |
|
|
$ |
49,482 |
|
|
|
|
|
|
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC.
AND SUBSIDIARIESRECONCILIATION OF NON-GAAP
METRICS(U.S. DOLLARS, IN
THOUSANDS)(Unaudited)
|
Three Months Ended September
30, |
|
Nine Months Ended
September 30, |
Reconciliation of GAAP
net income/(loss) to EBITDA (non-GAAP) |
2019 |
2018 |
|
2019 |
2018 |
GAAP net income/(loss) |
$ |
354 |
$ |
(6,380 |
) |
|
$ |
(14,609 |
) |
$ |
(26,859 |
) |
Add back: |
|
|
|
|
|
Provision for income taxes |
4 |
— |
|
|
4 |
|
53 |
|
Net interest expense |
1,237 |
2,569 |
|
|
17,727 |
|
7,606 |
|
Depreciation and amortization |
1,904 |
1,519 |
|
|
5,259 |
|
4,718 |
|
EBITDA |
$ |
3,499 |
$ |
(2,292 |
) |
|
$ |
8,381 |
|
$ |
(14,482 |
) |
Reconciliation of GAAP
net income/(loss) to Non-GAAP net income/(loss) |
|
|
|
|
|
GAAP net income/(loss) |
354 |
(6,380 |
) |
|
(14,609 |
) |
(26,859 |
) |
Non-GAAP adjustments: |
|
|
|
|
|
Stock-based compensation expense |
1,267 |
892 |
|
|
3,978 |
|
4,896 |
|
Amortization of intangible assets |
1,898 |
1,289 |
|
|
5,084 |
|
3,868 |
|
Amortization of warrant discount |
— |
269 |
|
|
448 |
|
807 |
|
Non-recurring financial impact of debt refinance |
— |
— |
|
|
11,866 |
|
— |
|
Non-GAAP net
income/(loss) |
$ |
3,519 |
$ |
(3,930 |
) |
|
$ |
6,767 |
|
$ |
(17,288 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2023 to Apr 2024